Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 521INDUSTRY 179NIH 20OTHER_GOV 14NETWORK 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 265Leukemia 183Carcinoma, Non-Small-Cell Lung 168Lymphoma 159Lung Neoplasms 148Prostatic Neoplasms 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Ovarian Neoplasms 117Colorectal Neoplasms 115Sarcoma 108Central Nervous System Neoplasms 107Head and Neck Neoplasms 98Leukemia, Myeloid, Acute 95Multiple Myeloma 93Squamous Cell Carcinoma of Head and Neck 83Rectal Neoplasms 77Colonic Neoplasms 71Uterine Cervical Neoplasms 65Neoplasm Metastasis 65Neuroblastoma 64Carcinoma, Ovarian Epithelial 64Brain Neoplasms 64Neoplasms 63Fallopian Tube Neoplasms 62Lymphoma, Large B-Cell, Diffuse 61Astrocytoma 59Melanoma 58Leukemia, Lymphocytic, Chronic, B-Cell 56Burkitt Lymphoma 56Hodgkin Disease 55

Interventions

olaparib 1durvalumab 1Taxes 1Platinum 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Cholangiocarcinoma × Clear all
NCT06441747 2026-05-06

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Australasian Gastro-Intestinal Trials Group

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03768414 2026-01-12

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

SWOG Cancer Research Network

Phase 3 Completed
452 enrolled 17 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT01862276 2014-07-01

Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma

Kansai Hepatobiliary Oncology Group

Completed
200 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡